Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71

Benzinga Newsdesk www.benzinga.com Positive 81.8%

Neg 0% Neu 0% Pos 81.8%

Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.